http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View More Recent Stories
-
Blueprint Medicines Reports Second Quarter 2019 Financial Results
-
Blueprint Medicines to Report Second Quarter 2019 Financial Results on Thursday, August 1, 2019
-
Blueprint Medicines (BPMC) Announces EMA Validation of MAA for Avapritinib for the Treatment of PDGFRα D842V Mutant GIST and Fourth-Line GIST
-
Blueprint Medicines Announces European Medicines Agency Validation of Marketing Authorization Application for Avapritinib for the Treatment of PDGFRα D842V Mutant GIST and Fourth-Line GIST
-
Blueprint Medicines (BPMC) Reports Updated EXPLORER Trial Data for Avapritinib in Patients with Systemic Mastocytosis
-
Blueprint Medicines Presents Updated EXPLORER Trial Data for Avapritinib in Patients with Systemic Mastocytosis at 24th EHA Congress
-
Blueprint Medicines (BPMC) Submits NDA to FDA for Avapritinib for Treatment of PDGFRA Exon 18 Mutant GIST and Fourth-Line GIST
-
Blueprint Medicines Submits New Drug Application to U.S. Food and Drug Administration for Avapritinib for the Treatment of PDGFRA Exon 18 Mutant GIST and Fourth-Line GIST
-
Blueprint Medicines (BPMC) Reports Updated Data from Ongoing ARROW Trial of BLU-667 at ASCO 2019 Meeting
-
Blueprint Medicines' Highly Selective RET Inhibitor BLU-667 Shows Durable Anti-Tumor Activity in Patients with RET-Altered Cancers in Updated ARROW Trial Data Presented at ASCO 2019
-
Blueprint Medicines Presents NAVIGATOR Trial Data in PDGFRA Exon 18 Mutant GIST and Fourth-Line GIST at ASCO 2019 Supporting Planned Marketing Applications for Avapritinib
-
Blueprint Medicines to Present at Upcoming Investor Conferences in June
-
Blueprint Medicines Announces Data Presentations at ASCO and EHA Meetings from Registration-Enabling Clinical Trials of Avapritinib and BLU-667 Across Multiple Patient Populations
-
Blueprint Medicines Reports First Quarter 2019 Financial Results
-
Blueprint Medicines to Present at Bank of America Merrill Lynch 2019 Health Care Conference
-
Blueprint Medicines to Report First Quarter 2019 Financial Results on Thursday, May 9, 2019
-
Blueprint Medicines to Present at 39th Annual Cowen & Co. Health Care Conference
-
Blueprint Medicines Reports Fourth Quarter and Full Year 2018 Financial Results
-
Blueprint Medicines to Report Fourth Quarter and Full Year 2018 Financial Results on Tuesday, February 26, 2019
-
Blueprint Medicines to Present at Upcoming Investor Conferences in February
-
Blueprint Medicines (BPMC) Provides '2020 Blueprint' Global Business Strategy & Outlines Key Corporate Goals
-
Blueprint Medicines Announces "2020 Blueprint" Global Business Strategy and Outlines Key Corporate Goals
-
Blueprint Medicines Reports Fourth Quarter and Full Year 2017 Financial Results
-
Blueprint Medicines Reports Third Quarter 2017 Financial Results
-
Blueprint Medicines Reports Second Quarter 2017 Financial Results

